vs
Side-by-side financial comparison of Strive, Inc. (ASST) and IGC Pharma, Inc. (IGC). Click either name above to swap in a different company.
Strive, Inc. is the larger business by last-quarter revenue ($255.0K vs $191.0K, roughly 1.3× IGC Pharma, Inc.). IGC Pharma, Inc. runs the higher net margin — -953.4% vs -75406.7%, a 74453.3% gap on every dollar of revenue. On growth, IGC Pharma, Inc. posted the faster year-over-year revenue change (-53.6% vs -74.1%). Over the past eight quarters, Strive, Inc.'s revenue compounded faster (77.6% CAGR vs -19.0%).
Strive Asset Management is an American investment management firm founded in 2022. The firm operates mutual funds, exchange-traded products (ETPs), and wealth management services. Headquartered in Columbus, Ohio, it operates as a subsidiary of Strive Enterprises, Inc. and is registered with the U.S. Securities and Exchange Commission (SEC) as an investment adviser.
IGC Pharma, Inc. is a clinical-stage biopharmaceutical firm focused on developing and commercializing innovative cannabinoid-derived therapeutics. Its core pipeline targets treatments for neurodegenerative conditions, pain and rare diseases, with primary operations in North America and ongoing global market expansion.
ASST vs IGC — Head-to-Head
Income Statement — Q3 FY2025 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $255.0K | $191.0K |
| Net Profit | $-192.3M | $-1.8M |
| Gross Margin | — | 51.8% |
| Operating Margin | -17288.6% | -1517.8% |
| Net Margin | -75406.7% | -953.4% |
| Revenue YoY | -74.1% | -53.6% |
| Net Profit YoY | -2726.9% | -6.1% |
| EPS (diluted) | $-0.22 | $-0.02 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q3 25 | $255.0K | $191.0K | ||
| Q2 25 | $173.3K | $328.0K | ||
| Q1 25 | $170.7K | — | ||
| Q4 24 | $212.8K | $257.0K | ||
| Q3 24 | $984.0K | $412.0K | ||
| Q2 24 | $93.0K | $272.0K | ||
| Q1 24 | $124.8K | $295.0K | ||
| Q4 23 | $80.9K | $204.0K |
| Q3 25 | $-192.3M | $-1.8M | ||
| Q2 25 | $-8.9M | $-1.6M | ||
| Q1 25 | $-3.7M | — | ||
| Q4 24 | $-4.1M | $-1.8M | ||
| Q3 24 | $-6.8M | $-1.7M | ||
| Q2 24 | $-5.9M | $-2.4M | ||
| Q1 24 | $-4.8M | $-2.9M | ||
| Q4 23 | $-1.3M | $-5.6M |
| Q3 25 | — | 51.8% | ||
| Q2 25 | — | 47.0% | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 40.5% | ||
| Q3 24 | — | 48.1% | ||
| Q2 24 | — | 59.9% | ||
| Q1 24 | — | 58.0% | ||
| Q4 23 | — | 65.2% |
| Q3 25 | -17288.6% | -1517.8% | ||
| Q2 25 | -1553.9% | -580.8% | ||
| Q1 25 | -970.5% | — | ||
| Q4 24 | -5889.5% | -730.7% | ||
| Q3 24 | -712.4% | -427.2% | ||
| Q2 24 | -1857.2% | -880.9% | ||
| Q1 24 | -1110.9% | -735.6% | ||
| Q4 23 | -1667.7% | -1469.6% |
| Q3 25 | -75406.7% | -953.4% | ||
| Q2 25 | -5122.4% | -487.5% | ||
| Q1 25 | -2195.6% | — | ||
| Q4 24 | -1935.5% | -711.7% | ||
| Q3 24 | -691.3% | -416.7% | ||
| Q2 24 | -6313.1% | -874.3% | ||
| Q1 24 | -3837.7% | -978.0% | ||
| Q4 23 | -1667.7% | -2739.7% |
| Q3 25 | $-0.22 | $-0.02 | ||
| Q2 25 | $-0.17 | $-0.02 | ||
| Q1 25 | $-0.13 | — | ||
| Q4 24 | $-5.62 | $-0.02 | ||
| Q3 24 | $-3.06 | $-0.02 | ||
| Q2 24 | $-0.58 | $-0.03 | ||
| Q1 24 | $-0.49 | — | ||
| Q4 23 | $-0.88 | $-0.09 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $109.1M | $1.1M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $779.4M | $8.1M |
| Total Assets | $792.6M | $9.7M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q3 25 | $109.1M | $1.1M | ||
| Q2 25 | $2.5M | $454.0K | ||
| Q1 25 | $4.2M | — | ||
| Q4 24 | $6.2M | $470.0K | ||
| Q3 24 | $2.1M | $1.5M | ||
| Q2 24 | $1.9M | $1.8M | ||
| Q1 24 | $1.9M | $1.2M | ||
| Q4 23 | $2.9M | $1.4M |
| Q3 25 | $779.4M | $8.1M | ||
| Q2 25 | $10.7M | $6.1M | ||
| Q1 25 | $19.6M | — | ||
| Q4 24 | $23.3M | $6.3M | ||
| Q3 24 | $27.5M | $7.4M | ||
| Q2 24 | $5.4M | $7.9M | ||
| Q1 24 | $11.3M | — | ||
| Q4 23 | $16.1M | $9.1M |
| Q3 25 | $792.6M | $9.7M | ||
| Q2 25 | $3.3M | $7.9M | ||
| Q1 25 | $5.0M | — | ||
| Q4 24 | $28.2M | $9.1M | ||
| Q3 24 | $2.6M | $10.4M | ||
| Q2 24 | $2.4M | $10.6M | ||
| Q1 24 | $2.1M | $9.9M | ||
| Q4 23 | $3.1M | $11.3M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-14.0M | $-2.1M |
| Free Cash FlowOCF − Capex | — | $-2.1M |
| FCF MarginFCF / Revenue | — | -1109.4% |
| Capex IntensityCapex / Revenue | 0.0% | 15.2% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q3 25 | $-14.0M | $-2.1M | ||
| Q2 25 | $-1.7M | $-1.4M | ||
| Q1 25 | $-1.6M | — | ||
| Q4 24 | $-21.6M | — | ||
| Q3 24 | $-13.2M | $-996.0K | ||
| Q2 24 | $-1.3M | $-1.8M | ||
| Q1 24 | $-1.0M | $-526.0K | ||
| Q4 23 | $-854.1K | $-1.6M |
| Q3 25 | — | $-2.1M | ||
| Q2 25 | — | $-1.4M | ||
| Q1 25 | — | — | ||
| Q4 24 | $-21.6M | — | ||
| Q3 24 | $-13.4M | $-1.0M | ||
| Q2 24 | $-1.3M | $-1.8M | ||
| Q1 24 | $-1.1M | $-541.0K | ||
| Q4 23 | — | $-1.7M |
| Q3 25 | — | -1109.4% | ||
| Q2 25 | — | -431.4% | ||
| Q1 25 | — | — | ||
| Q4 24 | -10161.2% | — | ||
| Q3 24 | -1360.3% | -248.8% | ||
| Q2 24 | -1379.4% | -658.1% | ||
| Q1 24 | -844.7% | -183.4% | ||
| Q4 23 | — | -811.3% |
| Q3 25 | 0.0% | 15.2% | ||
| Q2 25 | — | 2.4% | ||
| Q1 25 | — | — | ||
| Q4 24 | 11.3% | — | ||
| Q3 24 | 18.8% | 7.0% | ||
| Q2 24 | 3.1% | 14.0% | ||
| Q1 24 | 9.5% | 5.1% | ||
| Q4 23 | — | 33.3% |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
